ID   M238
AC   CVCL_D751
DR   cancercelllines; CVCL_D751
DR   Cosmic; 1425352
DR   Cosmic; 1459647
DR   Cosmic; 1665013
DR   GEO; GSM612087
DR   GEO; GSM612088
DR   GEO; GSM1588917
DR   Progenetix; CVCL_D751
DR   Wikidata; Q54903550
RX   PubMed=20406486;
RX   PubMed=20689758;
RX   PubMed=22194965;
RX   PubMed=22515704;
RX   PubMed=24735930;
RX   PubMed=28196595;
RX   PubMed=29229836;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 28.1 hours (PubMed=20406486).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=20406486).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (PubMed=20406486; PubMed=22194965).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486; PubMed=22194965).
CC   Omics: Protein expression by reverse-phase protein arrays.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 17
//
RX   PubMed=20406486; DOI=10.1186/1479-5876-8-39;
RA   Sondergaard J.N., Nazarian R., Wang Q., Guo D.-L., Hsueh T., Mok S.,
RA   Sazegar H., MacConaill L.E., Barretina J.G., Kehoe S.M., Attar N.,
RA   von Euw E.M., Zuckerman J.E., Chmielowski B., Comin-Anduix B.,
RA   Koya R.C., Mischel P.S., Lo R.S., Ribas A.;
RT   "Differential sensitivity of melanoma cell lines with BRAFV600E
RT   mutation to the specific Raf inhibitor PLX4032.";
RL   J. Transl. Med. 8:39.1-39.11(2010).
//
RX   PubMed=20689758; DOI=10.1593/neo.10414;
RA   Tap W.D., Gong K.-W., Dering J., Tseng Y., Ginther C., Pauletti G.,
RA   Glaspy J.A., Essner R., Bollag G., Hirth P., Zhang C., Slamon D.J.;
RT   "Pharmacodynamic characterization of the efficacy signals due to
RT   selective BRAF inhibition with PLX4032 in malignant melanoma.";
RL   Neoplasia 12:637-649(2010).
//
RX   PubMed=22194965; DOI=10.1371/journal.pone.0028973;
RA   Atefi M., von Euw E.M., Attar N., Ng C., Chu C., Guo D.-L., Nazarian R.,
RA   Chmielowski B., Glaspy J.A., Comin-Anduix B., Mischel P.S., Lo R.S.,
RA   Ribas A.;
RT   "Reversing melanoma cross-resistance to BRAF and MEK inhibitors by
RT   co-targeting the AKT/mTOR pathway.";
RL   PLoS ONE 6:E28973-E28973(2011).
//
RX   PubMed=22515704; DOI=10.1186/1476-4598-11-22;
RA   von Euw E.M., Atefi M., Attar N., Chu C., Zachariah S., Burgess B.L.,
RA   Mok S., Ng C., Wong D.J.L., Chmielowski B., Lichter D.I., Koya R.C.,
RA   McCannel T.A., Izmailova E., Ribas A.;
RT   "Antitumor effects of the investigational selective MEK inhibitor
RT   TAK733 against cutaneous and uveal melanoma cell lines.";
RL   Mol. Cancer 11:22.1-22.9(2012).
//
RX   PubMed=24735930; DOI=10.1186/1476-4598-13-83;
RA   Lassen A., Atefi M., Robert L., Wong D.J.L., Cerniglia M.,
RA   Comin-Anduix B., Ribas A.;
RT   "Effects of AKT inhibitor therapy in response and resistance to BRAF
RT   inhibition in melanoma.";
RL   Mol. Cancer 13:83.1-83.14(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29229836; DOI=10.1073/pnas.1712064115;
RA   Su Y.-P., Wei W., Robert L., Xue M., Tsoi J., Garcia-Diaz A.,
RA   Homet Moreno B., Kim J., Ng R.H., Lee J.W., Koya R.C.,
RA   Comin-Anduix B., Graeber T.G., Ribas A., Heath J.R.;
RT   "Single-cell analysis resolves the cell state transition and signaling
RT   dynamics associated with melanoma drug-induced resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:13679-13684(2017).
//